[Treatment of chronic viral hepatitis with recombinant interferon-alfa].
The antiviral treatment with alfa-interferon is the first proven therapeutic possibility in chronic viral hepatitis. The rate of improvement to alfa-interferon ranges between 15-40% depending on the type of hepatitis. The optimal dose is 5 MU/day three times a week for 6 months in chronic hepatitis B, while 3 MU/day three times a week for months in chronic hepatitis C. Results of therapy can be improved using combination treatment in selected cases.
Peter
F
F
IV. sz. Egyetemi Belgyógyászati Klinika, Universität Wien, Austria.
D002908:Chronic Disease; D006509:Hepatitis B / Q000188:drug therapy / Q000276:immunology; D006510:Hepatitis B Antibodies / Q000276:immunology; D006511:Hepatitis B Antigens / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D006521:Hepatitis, Chronic / Q000188:drug therapy* / Q000276:immunology; D006525:Hepatitis, Viral, Human / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D011994:Recombinant Proteins
D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens; D006514:Hepatitis B Surface Antigens; D007370:Interferon Type I; D011994:Recombinant Proteins
A krónikus virushepatitis kezelése rekombináns alfa-interferonnal.